4 not yet recruiting. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Not yet recruiting 4 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Colitis: new trials by email Literature Review of Colitis trials Research Report on Colitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nitazoxanide as Adjunct Therapy in Mild-to-Moderate Ulcerative Colitis Nitazoxanide (NTZ) - Ulcerative Colitis (UC) | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 44 | 2027-01-01 | 2026-09-15 |
| Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis Hemay005 tablet, Placebo - Ulcerative Colitis (UC) | Phase 3 | Not yet recruiting | Ganzhou Hemay Pharmaceutical Co., Ltd | 360 | 2026-06-01 | 2026-06-16 |
| Risankizumab for Fibrostenotic Crohn's Disease Treatment Ustekinumab, Risankizumab - Crohn Disease, Crohn Disease and Ulcerative Colitis | Phase 3 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 260 | 2025-10-20 | 2025-09-16 |
| Vedolizumab in Pediatric Ulcerative Colitis- Comparison With Infliximab Infliximab - Ulcerative Colitis | Phase 3 | Not yet recruiting | JAROSLAW KIERKUS | 60 | 2024-10-01 | 2024-09-26 |
Colitis, Ulcerative (4) · Crohn Disease (1) · Inflammatory Bowel Diseases (1)
Colonic Diseases (4) · Digestive System Diseases (4) · Gastroenteritis (4) · Gastrointestinal Diseases (4) · Intestinal Diseases (4) · Inflammatory Bowel Diseases (3)
Hemay005 (1) · Infliximab (1) · Ustekinumab (1) · nitazoxanide (1) · risankizumab (1) · vedolizumab (1)
First Affiliated Hospital of Wenzhou Medical University (1) · Ganzhou Hemay Pharmaceutical Co., Ltd (1) · JAROSLAW KIERKUS (1) · Tanta University (1)
China (1)
Minhu Chen, M.D (1)